Cardiometabolic News and Research

RSS

Maintaining weight loss may improve cardiometabolic profile in postmenopausal women

When you're postmenopausal and overweight, losing weight is a good thing, but gaining back just a few pounds may actually be detrimental to your cardiovascular health.

10 Dec 2012

METACARDIS project to develop and implement personalized treatments for patients with CMDs

Thanks to the support of the European Commission, fourteen partners in six European countries will work together over a five-year period to translate the results obtained with novel CMD diagnosis and treatment methods and pave the way for personalised medicine in CMDs. Researchers and clinicians from the Institute of Cardiometabolism and Nutrition (ICAN) will also be involved in the METACARDIS project.

5 Dec 2012

Pivotal Therapeutics reports loss of $811,164 for third quarter 2012

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on cardiovascular disease and overall health today announced its financial results and operational highlights for the quarter ended September 30, 2012. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.

30 Nov 2012

Atherotech VAP Lipid Panel demonstrates accuracy in personalized heart disease risk assessment

Researchers using the Atherotech VAP Lipid Panel demonstrated the comprehensive lipid profile's accuracy in risk stratification through subclass measurement in two abstracts presented today at the American Heart Association (AHA) Scientific Sessions 2012.

8 Nov 2012

Arisaph’s ARI-3037MO well tolerated in healthy male and female volunteers

Arisaph Pharmaceuticals, Inc. announced today during an oral presentation at the American Heart Association (AHA) meeting in Los Angeles, CA that its niacin analog, ARI-3037MO, was extremely well tolerated in a single-ascending dose (SAD) and a multiple-ascending dose (MAD) trial in healthy male and female volunteers.

7 Nov 2012

Kids encouraged to Stand Up for their health and be active

Children and adolescents are accumulating up to eight hours of sitting on a daily basis, research to be presented at Australia’s paramount sports medicine, sports science, sports injury prevention and physical activity promotion conference, be active2012 will show (October 31- November 3, Sydney).

16 Oct 2012

Neurotensin as an indicator for poor health outcomes in women

The satiety hormone neurotensin may provide a novel biomarker for assessing risk for diabetes, cardiovascular disease, and breast cancer among women, report researchers.

12 Oct 2012

Poor sleep shows cardiovascular links in adolescents

Sleep disturbance in healthy adolescents is associated with an increased risk for cardiovascular disease in later life, research suggests.

11 Oct 2012

Proneurotensin associated with diabetes, cardiometabolic disease and breast cancer

Plasma levels of proneurotensin are associated with the development of diabetes, cardiovascular disease, cardiovascular and total mortality, and breast cancer in women during long-term follow-up, according to a study in the October 10 issue of JAMA.

10 Oct 2012

Loss of IGSF1 gene function causes central hypothyroidism

Loss of function in the X-linked immunoglobulin superfamily member 1 (IGSF1) gene causes central hypothyroidism, testicular enlargement, and variable prolactin deficiency, according to data presented at the 82nd Annual Meeting of the American Thyroid Association in Québec City, Québec, Canada.

21 Sep 2012

ChromaDex announces findings from pTeroPure Phase 2/3 trial on high blood pressure

ChromaDex Corporation announced today findings from a Phase 2/3 trial at the University of Mississippi Medical Center showing its patented nutritional ingredient pTeroPure (pterostilbene) significantly reduced blood pressure in adults.

21 Sep 2012

High uric acid precursor of obesity, metabolic syndrome

The relationship between uric acid and early cardiometabolic risk may precede obesity and the metabolic syndrome, show study findings.

20 Sep 2012

Islet Sciences licenses noninvasive technology from Winthrop for detecting Beta cell death

Islet Sciences, Inc., a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from Winthrop University Hospital. This technology is complimentary to the early Beta cell destruction diagnostic that Islet Sciences licensed last month.

10 Sep 2012

Patients with psoriasis are at high risk of new-onset diabetes mellitus

Patients with psoriasis are at high risk of new-onset diabetes mellitus, according to research presented at ESC Congress 2012.

27 Aug 2012

Statins: cardiovascular benefits outweigh diabetes risk

The benefits of taking statins to reduce the risk of cardiovascular disease outweigh the increased risk of developing diabetes experienced by some patients who take these cholesterol-lowering drugs, according to an Article published Online First in The Lancet.

10 Aug 2012

Exercise benefits influenced by sRAGE levels in diabetes

Increased levels of the soluble form of the receptor for advanced glycation end products may underly the beneficial effects of exercise in patients with Type 2 diabetes, research shows.

3 Aug 2012

Diabetes on the rise among Chinese teenagers

A study led by researchers at the University of North Carolina at Chapel Hill found Chinese teenagers have a rate of diabetes nearly four times greater than their counterparts in the United States. The rise in the incidence of diabetes parallels increases in cardiovascular risk, researchers say, and is the result of a Chinese population that is growing increasingly overweight.

6 Jul 2012

ChromaDex’s pTeroPure safe for human consumption

ChromaDex Corporation, an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries announced today its patented pTeroPure (pterostilbene) was shown to be safe for human consumption according to data from the first clinical trial of the substance.

13 Jun 2012

Zafgen announces new data from two Phase 1 studies of beloranib on obesity

Zafgen, Inc., the world's first biopharmaceutical company dedicated to addressing the unmet need of severely obese patients, today announced new data from two Phase 1 studies of beloranib, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed significant weight loss and improvements in cardiometabolic risk markers in severely obese women.

11 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.